Wikipedia
Inotek Pharmaceuticals is a clinical-stage drug development company developing therapies with novel mechanisms to address significant diseases of the eye.
The Company's lead program, INO-8875, is being evaluated for the treatment of elevated intraocular pressure associated with open-angle glaucoma and ocular hypertension. INO-8875 has completed a Phase 1/2 clinical trial in glaucoma subjects. Treatment with INO-8875 was well tolerated and resulted in a statistically significant reduction in intraocular pressure.
Additionally, Inotek has a portfolio of emerging programs targeting a broad range of retinal diseases, including age-related macular degeneration and macular edema.
It is based in Lexington, Massachusetts.
Category:Biotechnology companies of the United States Category:Companies based in Middlesex County, Massachusetts Category:Lexington, Massachusetts Category:Companies listed on NASDAQ